Buformin

• UNSPSC Description:

  Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al)[1].

• Target Antigen:

  AMPK

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;PI3K/Akt/mTOR

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Cancer; Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/buformin.html

• Solubility:

  10 mM in DMSO

• Smiles:

  NC(NC(NCCCC)=N)=N

• Molecular Weight:

  157.22

• References & Citations:

  [1]Amanda B Parris, et al. Buformin Inhibits the Stemness of erbB-2-overexpressing Breast Cancer Cells and Premalignant Mammary Tissues of MMTV-erbB-2 Transgenic Mice. J Exp Clin Cancer Res|[2]Jing Li, et al. Buformin Suppresses Proliferation and Invasion via AMPK/S6 Pathway in Cervical Cancer and Synergizes With Paclitaxel. Cancer Biol Ther. 2018 Jun 3;19(6):507-517.ACS Appl Nano Mater. 2023 Oct 26.|Clin Sci. 2022 Feb 25;136(4):273-289.|Mol Metab. 2023 Dec 22:101860.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  692-13-7